Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:HEPANASDAQ:HSTONASDAQ:MYMDNASDAQ:VRPX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHEPAHepion Pharmaceuticals$0.06-15.6%$0.23$0.04▼$59.75$645K1.581.31 million shs279,655 shsHSTOHistogen$0.00-8.3%$0.03$0.05▼$0.55$5K1.1910,369 shs2,653 shsMYMDMyMD Pharmaceuticals$0.18+4.2%$0.20$1.75▼$63.90$417K2.15134,123 shs91.18 million shsVRPXVirpax Pharmaceuticals$0.24-8.3%$0.25$0.13▼$84.75$296K1.48202,555 shs3,690 shs10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHEPAHepion Pharmaceuticals-11.52%+66.43%-78.02%-96.30%-99.88%HSTOHistogen-8.33%-96.33%-96.62%-96.33%-99.39%MYMDMyMD Pharmaceuticals+4.20%+2.98%-7.32%-51.38%-90.88%VRPXVirpax Pharmaceuticals+0.04%+3.87%+6.16%-94.16%-98.55%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationHEPAHepion Pharmaceuticals1.2872 of 5 stars0.05.00.00.03.30.00.6HSTOHistogenN/AN/AN/AN/AN/AN/AN/AN/AMYMDMyMD PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AVRPXVirpax Pharmaceuticals1.5424 of 5 stars3.04.00.00.00.60.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHEPAHepion Pharmaceuticals 0.00N/AN/AN/AHSTOHistogen 0.00N/AN/AN/AMYMDMyMD Pharmaceuticals 0.00N/AN/AN/AVRPXVirpax Pharmaceuticals 2.00Hold$75.0031,333.36% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHEPAHepion PharmaceuticalsN/AN/AN/AN/A$1.29 per shareN/AHSTOHistogen$19K0.25N/AN/A$3.13 per share0.00MYMDMyMD PharmaceuticalsN/AN/AN/AN/A$7.21 per shareN/AVRPXVirpax PharmaceuticalsN/AN/AN/AN/A$1.65 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHEPAHepion Pharmaceuticals-$48.93M-$219.00N/A∞N/AN/A-812.56%-207.31%8/11/2025 (Estimated)HSTOHistogen-$10.62M-$2.81N/A∞N/AN/AN/AN/AN/AMYMDMyMD Pharmaceuticals-$4MN/A0.00∞N/AN/A-179.05%-108.14%N/AVRPXVirpax Pharmaceuticals-$15.19MN/A0.00∞N/AN/A-1,554.34%-338.29%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthHEPAHepion PharmaceuticalsN/AN/AN/AN/AN/AHSTOHistogenN/AN/AN/AN/AN/AMYMDMyMD PharmaceuticalsN/AN/AN/AN/AN/AVRPXVirpax PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHEPAHepion PharmaceuticalsN/A1.301.30HSTOHistogenN/AN/AN/AMYMDMyMD PharmaceuticalsN/A0.620.62VRPXVirpax PharmaceuticalsN/A0.130.13Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHEPAHepion Pharmaceuticals17.24%HSTOHistogenN/AMYMDMyMD Pharmaceuticals9.64%VRPXVirpax Pharmaceuticals32.23%Insider OwnershipCompanyInsider OwnershipHEPAHepion Pharmaceuticals0.06%HSTOHistogen3.30%MYMDMyMD Pharmaceuticals2.12%VRPXVirpax Pharmaceuticals3.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHEPAHepion Pharmaceuticals2010.94 million6.63 millionNo DataHSTOHistogen204.27 millionN/ANot OptionableMYMDMyMD Pharmaceuticals62.37 million2.32 millionOptionableVRPXVirpax Pharmaceuticals71.24 million4.71 millionNot OptionableHSTO, HEPA, MYMD, and VRPX HeadlinesRecent News About These CompaniesVirpax Pharmaceuticals stock plummets on Nasdaq delisting newsApril 3, 2025 | investing.comVirpax Pharmaceuticals Inc trading halted, news pendingMarch 21, 2025 | markets.businessinsider.comVirpax reports positive results in Probudur dog studyMarch 20, 2025 | investing.comVirpax receives positive Probudur results for dose range studyMarch 20, 2025 | markets.businessinsider.comVirpax Pharmaceuticals announces 1-for-25 reverse stock splitMarch 20, 2025 | markets.businessinsider.comVirpax Receives Positive Probudur™ Results for Dose Range Study Moves Towards Next Steps in INDMarch 19, 2025 | finance.yahoo.comVirpax Pharmaceuticals files to sell common stock and warrants, no amount givenMarch 18, 2025 | markets.businessinsider.comVirpax Pharmaceuticals Explores Intranasal mRNA Vaccine Delivery Using METMarch 11, 2025 | msn.comVirpax Pharmaceuticals to Present NES100 Toxicity Study at Major Toxicology ConferenceMarch 11, 2025 | msn.comVirpax Looking to Use MET to Develop Intranasal COVID VaccineMarch 7, 2025 | businesswire.comAnalysts Conflicted on These Healthcare Names: Clearside Biomedical (CLSD) and Virpax Pharmaceuticals (VRPX)March 6, 2025 | markets.businessinsider.comVirpax’s NES100 to be Presented at The Society of Toxicology by NCATSMarch 5, 2025 | finance.yahoo.comVirpax Pharmaceuticals Applauds Successful Trial of Molecular Envelope TechnologyMarch 3, 2025 | msn.comVirpax lauds Nanomerics’ MET study with no severe side effectsMarch 1, 2025 | investing.comVirpax Reports Positive Results in Human Study for its Molecular Envelope TechnologyFebruary 27, 2025 | finance.yahoo.comVirpax Reports Positive Results in Human Study for its Molecular Envelope TechnologyFebruary 27, 2025 | businesswire.comVirpax Confirms Positive Results with US Army with Probudur™ for Combat Care StudyFebruary 13, 2025 | joplinglobe.comVirpax Pharmaceuticals confirms results with U.S. Army with ProbudurFebruary 13, 2025 | markets.businessinsider.comVirpax reports positive study results for pain management drugFebruary 13, 2025 | msn.comVirpax Pharmaceuticals appoints new independent directorFebruary 6, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHSTO, HEPA, MYMD, and VRPX Company DescriptionsHepion Pharmaceuticals NASDAQ:HEPA$0.06 -0.01 (-15.59%) As of 03:50 PM EasternHepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.Histogen NASDAQ:HSTO$0.0011 0.00 (-8.33%) As of 06/10/2025Histogen Inc., a clinical-stage therapeutics company, focuses on developing clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body's natural process to restore immune function. The company's product candidates include emricasan for the treatment of acute bacterial skin and skin structure infections, as well as other infectious diseases. Its preclinical product candidates include CTS-2090 and CTS-2096, which are selective small molecule inhibitors of caspase-1 designed for the treatment of various inflammatory diseases. Histogen Inc. was founded in 2007 and is based in San Diego, California. On April 18, 2024, Histogen Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of California.MyMD Pharmaceuticals NASDAQ:MYMD$0.18 +0.01 (+4.20%) As of 06/10/2025MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the aging and age-related and autoimmune diseases, and chronic pain, anxiety, and sleep disorders. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system and its pro-inflammatory cytokines to prevent and treat autoimmune diseases and age-related illnesses, and a Phase 2 clinical trial for sarcopenia, multiple sclerosis, diabetes, inflammatory bowel diseases, and rheumatoid arthritis; inflammation related depression and anxiety; and COVID-19-associated depression. It is also developing Supera-CBD, a synthetic analog of cannabidiol for treating epilepsy, pain, and anxiety/depression. The company was founded in 2014 and is headquartered in Baltimore, Maryland.Virpax Pharmaceuticals NASDAQ:VRPX$0.24 -0.02 (-8.27%) As of 03:47 PM EasternVirpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also comprise AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and NobrXiol, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ignore the Noise—Samsara Stock Is Still a Strong Buy Oracle’s Cloud Boom Is Just Getting Started Netflix Sets New Highs—Price Targets Keep Climbing IonQ’s $1B Acquisition and Drug Discovery Leap With NVIDIA Alibaba’s Dip Is a Gift—Here’s the Price That Matters Betting on Disruption: Is Lemonade the Future of Insurance? Starbucks Stock: Culture Fix May Be Key to Long-Term Growth GameStop Turns a Profit, But Core Business Keeps Shrinking Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
